Cell protective methods and compositions
Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.
1. A method of treating histone toxicity in a subject, the method comprising:
providing a subject in need of histone toxicity treatment; and
administering to the subject a chondroitin sulfate (CS) compound,
wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof, and
wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof, and
wherein the histone toxicity in the subject is treated.
2. The method of claim 1 , wherein the subject is suffering from sepsis.
3. The method of claim 1 , wherein the subject is a human subject.
4. The method of claim 1 , wherein the chondroitin sulfate compound comprises one or more of the following structures:
wherein R is selected from the group consisting of —H, alkyl, substituted alkyl, aryl, and substituted aryl, wherein n is 1, 2, 3, 4, 5, 6, 7 or 8.
5. The method of claim 1 , wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition.
6. The method of claim 1 , wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS.
7. A method of treating sepsis in a subject, the method comprising:
providing a subject in need of sepsis treatment; and
administering to the subject a chondroitin sulfate compound, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof, and
wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof wherein the sepsis in the subject is treated.
8. The method of claim 7 , wherein the subject is a human subject.
9. The method of claim 7 , wherein the chondroitin sulfate compound comprises one or more of the following structures:
wherein R is selected from the group consisting of —H, alkyl, substituted alkyl, aryl, and substituted aryl, wherein n is 1, 2, 3, 4, 5, 6, 7 or 8.
10. The method of claim 7 , wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition.
11. The method of claim 7 , wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS.
12. The method of claim 4 , wherein the alkyl is —CH 3 or —CH 2 CH 3 or the substituted aryl is a p-nitrophenyl group.
13. The method of claim 9 , wherein the alkyl is —CH 3 or —CH 2 CH 3 or the substituted aryl is a p-nitrophenyl group.